Prespecified secondary analysis of REPRIEVE (4989 adults with HIV without hypertension): pitavastatin vs placebo modestly lowered incident hypertension (24.7 vs 29.6/1000 person-years; HR 0.83, 95% CI 0.71-0.97) over median 5 years.
Secondary analysisn = 4,989
Martínez et al. Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trial